G

Gilead Sciences

Makes medicines for HIV, liver disease and cancer

Director – Global Value and Access Strategy - Cell-Therapy Autoimmune

Product MarketingConfirmed live in the last 24 hours
Full-time

About the Job

Requirements

  • At least 8 years of experience with a PhD or PharmD; or at least 10 years with an MS/MA, MBA, PharmD, PhD, or equivalent advanced degree; or at least 12 years with a BS/BA.
  • At least 3 years of direct experience supporting autoimmune disease programs, including development-stage assets, clinical strategy, market access, medical affairs, commercial strategy, or related functions.
  • Deep understanding of autoimmune disease treatment paradigms, competitive dynamics, and unmet patient needs.
  • Experience in advanced therapies, including cell therapy and/or gene therapy, is strongly preferred.
  • Experience supporting market access, pricing, reimbursement, health economics and outcomes research (HEOR), commercial strategy, or related functions within the pharmaceutical or biotechnology industry.
  • Experience supporting early- and/or late-stage development programs and translating payer insights into development decisions.
  • Demonstrated experience incorporating payer, health technology assessment (HTA), and health system requirements into clinical development and evidence generation strategies.
  • Experience supporting launch readiness activities, global launch planning, and lifecycle management.
  • Strong understanding of global payer, pricing, reimbursement, and HTA landscapes.
  • Experience partnering with HEOR, real-world evidence (RWE), Medical Affairs, Clinical Development, and Commercial functions to develop value evidence strategies.
  • Understanding of value frameworks, reimbursement pathways, and evidence requirements across major global markets.
  • Demonstrated ability to influence cross-functional teams in a matrix environment.
  • Strong strategic thinking, analytical, and problem-solving skills.
  • Excellent communication skills and experience presenting to senior leadership.
  • Ability to collaborate across functions, regions, cultures, and time zones.
  • Ability to work in a fast-paced environment characterized by innovation and portfolio growth.

Responsibilities

  • Serve as the Global Market Access representative for assigned autoimmune programs and contribute to cross-functional conversations.
  • Lead and partner with global and regional Value Access, HEOR/RWE, and Commercial functions in the Value Access Sub-Team to integrate access input into portfolio strategy.
  • Lead the development of global value and access strategies across the product lifecycle, from early development through launch and lifecycle management.
  • Ensure payer, HTA, and health system perspectives are reflected in development, evidence generation, pricing, and commercialization strategies.
  • Partner with regional and country access teams to develop integrated global-to-local reimbursement strategies.
  • Analyze market access trends, evolving reimbursement requirements, competitive dynamics, and health system considerations across major markets, including the US, EU5, Canada, Australia, and Japan.
  • Provide market access input into target product profiles, clinical development plans, endpoint selection, comparator strategy, study design, and evidence generation plans.
  • Advise development teams on evidence requirements needed to support future reimbursement, pricing, and formulary access decisions.
  • Ensure access-relevant considerations are incorporated into development milestones and governance decisions.
  • Partner with Clinical, HEOR, RWE, and Medical Affairs to develop and execute early payer engagement and HTA scientific advice strategies across multiple autoimmune indications, incorporating payer perspectives into evidence generation and development plans.
  • Provide strategic leadership on US market access dynamics across autoimmune indications, including payer formulary management, utilization management such as step edits and prior authorization, and rebate contracting strategies; incorporate these considerations into development, evidence generation, pricing, and launch planning.
  • Lead cross-functional assessment of payer, HTA, and health system evidence requirements across key global markets and translate insights into recommendations for clinical development programs.
  • Assess access implications of development opportunities across autoimmune indications and advise governance teams on the likelihood of favorable pricing, reimbursement, and patient access outcomes.
  • Partner with HEOR, RWE, Medical Affairs, and Commercial teams to develop value propositions and evidence packages.
  • Advise on the development of economic models, burden-of-illness studies, indirect treatment comparisons, and other payer-focused evidence.
  • Act as the market access lead within cross-functional teams, ensuring alignment across Development, Medical Affairs, Commercial, Regulatory Affairs, Pricing, and HEOR.
  • Influence strategic decisions through assessment of payer expectations, reimbursement risks, and value opportunities.
  • Model inclusive leadership and foster an environment where diversity and belonging drive innovation and performance.
  • Understand employees’ skills, experiences, aspirations, and potential, and provide coaching and development opportunities to support their growth and career goals.
  • Align teams to organizational priorities, remove barriers, encourage accountability, and create an environment where individuals can do their best work.

Desired Qualifications

  • Experience in advanced therapies, including cell therapy and/or gene therapy.

About the Company

Gilead Sciences

Makes medicines for HIV, liver disease and cancer

Gilead Sciences is a biopharmaceutical company that discovers, develops and sells medicines for HIV, viral hepatitis and other liver diseases, cancer and inflammatory conditions. Its HIV business covers both treatment, led by the once-daily pill Biktarvy, and prevention, including Descovy and Yeztugo, a lenacapavir injection given twice a year. In cancer, its Kite unit makes CAR T-cell therapies from patients' own immune cells, and Trodelvy is an antibody-drug conjugate for breast cancer. Gilead earns revenue by selling its drugs to wholesalers, specialty pharmacies, hospitals and governments worldwide after regulatory approval. The company was founded in 1987 and is headquartered in Foster City, California.

Company size
10,001+
Company stage
IPO
Headquarters
Foster City, CA
Founded
1987

Recently Posted Jobs

Explore more opportunities at Gilead Sciences

See more jobs